Lack of interaction between etifoxine and CRF1 and CRF2 receptors in rodents

Neuroscience Research

Volumn 56, Issue 1, 2006, Pages 53-60

  Verleye, Marc ^a   André, Nathalie ^a   Gillardin, Jean Marie ^a  

^a Service de Pharmacologie   (France)

Author keywords

Anxiety; Binding studies; cAMP assays; Corticotropin releasing factor; Etifoxine; Rodent

Indexed keywords

ANXIOLYTIC AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; ETIFOXINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MEMBRANE; CELL LINE; CONTROLLED STUDY; DRUG BINDING; GABAERGIC TRANSMISSION; GROOMING; HUMAN; HUMAN CELL; LOCOMOTION; MALE; MOOD DISORDER; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; RODENT; STOMACH EMPTYING; SYNAPTIC TRANSMISSION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; CELL LINE, TUMOR; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; GASTRIC EMPTYING; HUMANS; MALE; MICE; OXAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 33748153250     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2006.05.005     Document Type: Article

References (64)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Psychiatric Disorders (DSM-IV). Fourth ed. (1995), APA Press, Washington, DC
2. Ayala A.R., Pushkas J., Higley J.D., Ronsaville D., Gold P.W., Chroussos G.P., Pacak K., Calis K.A., Gerald M., Lindell S., Rice K.C., and Cizza G. Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm. J. Clin. Endocrinol. Metab. 89 (2004) 5729-5737
3. Bale T.L., Lee K.F., and Vale W.W. The role of corticotropin-releasing factor receptors in stress and anxiety. Integ. Comp. Biol. 42 (2002) 552-555
4. Bale T.L., and Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 525-557
5. Behan D.P., Grigoriadis D.E., Lovenberg T., Chalmers D., Heinrichs S., Liaw C., and De Souza E.B. Neurobiology of corticotropin-releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol. Psychiatry 1 (1996) 265-277
6. Boissier J.R., Simon P., Zaczinska M., and Fichelle J. Experimental psychopharmacologic study of a new psychotropic drug, 2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine. Therapie 27 (1972) 325-338
7. Bourin M., and Lambert O. Pharmacotherapy of anxious disorders. Hum. Psychopharmacol. Clin. Exp. 17 (2002) 383-400
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
9. Calogero A.E., Gallucci W.T., Chrousos G.P., and Gold P.W. Interaction between GABAergic neurotransmission and rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Res. 463 (1988) 28-36
10. Coskun T., Bozkurt A., Alican I., Ozkutlu U., Kurtel H., and Yegen B.C. Pathways mediating CRF-induced inhibition of gastric emptying in rats. Regul. Pept. 69 (1997) 113-120
11. Cullinan W.E. GABA(A) receptor subunit expression within hypophysiotropic CRH neurons: a dual hybridization histochemical study. J. Comp. Neurol. 419 (2000) 344-351
12. Dautzenberg F.M., and Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 23 (2002) 71-77
13. De Groote L., Penalva R.G., Flachskamm C., Reul J.M., and Linthorst A.C. Differential monoaminergic, neuroendocrine, and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J. Neurochem. 94 (2005) 45-56
14. De Souza E.B. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J. Neurosci. 7 (1987) 88-100
15. Dieterich K.D., and De Souza E.B. Functional corticotropin-releasing factor receptors in human neuroblastoma cells. Brain Res. 733 (1996) 113-118
16. Dunn A.J., and Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res. Rev. 15 (1990) 71-100
17. Grammatopoulos D., Milton N.G., and Hillhouse E.W. The human myometrial CRH receptor: G proteins and second messengers. Mol. Cell Endocrinol. 99 (1994) 245-250
18. Grammatopoulos D.K., and Chrousos G.P. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol. Metab. 13 (2002) 436-444
19. Habib K.E., Weld K.P., Rice K.C., Pushkas J., Champoux M., Listwak S., Webster E.L., Atkinson A.J., Schulkin J., Contoreggi C., Chrousos G.P., McCann S.M., Suomi S.J., Higley J.D., and Gold P.W. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6079-6084
20. Haley T.J., and McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12 (1957) 12-15
21. A receptors are mediated by the β subunit. Neuropharmacology 45 (2003) 293-303
22. Hillhouse E.W., Randeva H., Ladds G., and Grammatopoulos D. Corticotropin-releasing hormone receptors. Biochem. Soc. Trans. 30 (2002) 428-432
23. Hogg J.E., Myers J., and Hutson P.H. The human neuroblastoma cell line, IMR-32, expresses functional corticotropin-releasing factor receptors. Eur. J. Pharmacol. 312 (1996) 257-261
24. Holmes A., Heilig M., Rupniak N.M., Steckler T., and Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24 (2003) 580-588
25. Holsboer F., Von Bardeleben U., Gerken A., Stalla G.K., and Muller O.A. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. 311 (1984) 1127
26. Kagamiishi Y., Yamamoto T., and Watanabe S. Hippocampal serotonergic is involved in anxiety-like behavior induced by corticotropin-releasing factor. Brain Res. 991 (2003) 212-221
27. Kalueff A.V., and Tuohimaa P. Contrasting grooming phenotypes in C57Bl/6 and 129S1/SvImJ mice. Brain Res. 1028 (2004) 75-82
28. Kalueff A.V., and Tuohimaa P. Mouse grooming microstructure is a reliable anxiety marker bidirectionally sensitive to GABAergic drugs. Eur. J. Pharmacol. 508 (2005) 147-153
29. Koob G.F. Corticotropin-releasing factor, norepinephrine, and stress. Biol. Psychiatry 46 (1999) 1167-1180
30. Lazosky A.J., and Britton D.R. Effects of 5-HT-1A receptor agonists on CRF-induced behavior. Psychopharmacology (Berl) 104 (1991) 132-136
31. Linthorst A.C., Flachskamm C., Hopkins S.J., Hoadley M.E., Labeur M.S., Holsboer F., and Reul J.M. Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory challenge. J. Neurosci. 17 (1997) 4448-4460
32. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., and Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232 (1986) 1004-1007
33. Martinez V., Wang L., Rivier J.E., Vale W., and Taché Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J. Pharmacol. Exp. Ther. 301 (2002) 611-617
34. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 83-244
35. Morley J.E., and Levine A.S. Corticotrophin releasing factor, grooming and ingestive behavior. Life Sci. 31 (1982) 1459-1464
36. Murphy E.K., Sved A.F., and Finlay J.M. Corticotropin-releasing hormone receptor blockade fails to alter stress-evoked catecholamine release in prefrontal cortex of control or chronically stressed rats. Neuroscience 116 (2003) 1081-1087
37. Nemeroff C.B. Psychopharmacology of affective disorders in the 21st century. Biol. Psychiatry 44 (1998) 517-525
38. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., and Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226 (1984) 1342-1344
39. Owens M.J., and Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43 (1991) 425-473
40. Patchev V.K., Shoaib M., Holsboer F., and Almeida O.F. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 62 (1994) 265-271
41. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. second ed. (1986), Academic Press, Orlando, FL
42. Pedigo N.W., Dewey W.L., and Harris L.S. Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice. J. Pharmacol. Exp. Ther. 193 (1975) 845-852
43. Pelleymounter M.A., Joppa M., Ling N., and Foster A.C. Pharmacological evidence supporting a role for central corticotropin-releasing factor (2) receptors in behavioral, but not endocrine, response to environmental stress. J. Pharmacol. Exp. Ther. 302 (2002) 145-152
44. Perrin M.H., and Vale W.W. Corticotropin-releasing factor receptors and their ligand family. Ann. N.Y. Acad. Sci. 885 (1999) 312-328
45. 2 exert both additive and opposing influences on defensive startle behavior. J. Neurosci. 24 (2004) 6545-6552
46. Rivier J., Rivier C., and Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 224 (1984) 889-891
47. Schlichter R., Rybalchenko V., Poisbeau P., Verleye M., and Gillardin J.M. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 39 (2000) 1523-1535
48. 1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells. Fundam. Clin. Pharmacol. 13 (1999) 484-489
49. Serra M., Concas A., Mostallino M.C., Chessa M.F., Stomati M., Petraglia F., Genazzani A.R., and Biggio G. Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotrophin-releasing factor concentrations in rat brain. Psychoneuroendocrinology 24 (1999) 269-284
50. Servant D., Graziani P.L., Moyse D., and Parquet P.J. Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study. Encephale 24 (1998) 569-574
51. Sheldon R.J., Qi J.A., Porreca F., and Fisher L.A. Gastrointestinal motor effects of corticotropin-releasing factor in mice. Regul. Pept. 28 (1990) 137-151
52. Taché Y., Martinez V., Million M., and Wang L. Stress and the gastrointestinal tract. III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 280 (2001) G173-G177
53. Takahashi L.K. CRF(2) receptors: an emerging role in anxiety. Drug News Perspect. 15 (2002) 97-101
54. To C.T., Anheuer Z.E., and Bagdy G. Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport 10 (1999) 553-555
55. Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W., and Zorrilla E.P. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. 943 (2002) 142-150
56. Vale W., Spiess J., Rivier C., and Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213 (1981) 1394-1397
57. Van Den Eede F., Van Broeckhoven C., and Claes S.J. Corticotropin-releasing factor-binding protein, stress and major depression. Ageing Res. Rev. 4 (2005) 213-239
58. Verleye M., Akwa Y., Liere P., Ladurelle N., Pianos A., Eychenne B., Schumacher M., and Gillardin J.M. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol. Biochem. Behav. 82 (2005) 712-720
59. Verleye M., and Gillardin J.M. Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. Physiol. Behav. 82 (2004) 891-897
60. Verleye M., Pansart Y., and Gillardin J.M. Effects of etifoxine on ligand binding to GABA(A) receptors in rodents. Neurosci. Res. 44 (2002) 167-172
61. Verleye M., Schlichter R., and Gillardin J.M. Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex. Neuroreport 10 (1999) 3207-3210
62. Wang L., Martinez V., Rivier J.E., and Taché Y. Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 (2001) R1401-R1410
63. Williams C.L., Peterson J.M., Villar R.G., and Burks T.F. Corticotropin-releasing factor directly mediates colonic responses to stress. Am. J. Physiol. 253 (1987) G582-G586
64. Zorrilla E.P., Taché Y., and Koob G.F. Nibbling at CRF receptor control of feeding and gastrocolonic motility. Trends Pharmacol. Sci. 24 (2003) 421-427